Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer

Enli Chen; Juan Wang; Hongtao Zhang; Yuwei Zhang; Chenfei Jia; Xueya Min; Yansong Liang

doi:10.5114/jcb.2021.106241

eISSN: 2081-2841
ISSN: 1689-832X

Journal of Contemporary Brachytherapy

Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links

Editorial System

Submit your Manuscript

3/2021
vol. 13

Send email

Copy url:

abstract:

Review paper

Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer

Enli Chen

¹

,

Juan Wang

²

,

Hongtao Zhang

²

,

Yuwei Zhang

¹

,

Chenfei Jia

¹

,

Xueya Min

¹

,

Yansong Liang

²

Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China
Department of Oncology, Hebei General Hospital, Shijiazhuang, Hebei, China

J Contemp Brachytherapy 2021; 13, 3: 347–357

DOI: https://doi.org/10.5114/jcb.2021.106241

Online publish date: 2021/05/18

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Chen E, Wang J, Zhang H, et al. Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer. Journal of Contemporary Brachytherapy. 2021;13(3):347-357. doi:10.5114/jcb.2021.106241.

APA

Chen, E., Wang, J., Zhang, H., Zhang, Y., Jia, C.,  & Min, X. et al. (2021). Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer. Journal of Contemporary Brachytherapy, 13(3), 347-357. https://doi.org/10.5114/jcb.2021.106241

Chicago

Chen, Enli, Juan Wang, Hongtao Zhang, Yuwei Zhang, Chenfei Jia, Xueya Min,  and Yansong Liang. 2021. "Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer". Journal of Contemporary Brachytherapy 13 (3): 347-357. doi:10.5114/jcb.2021.106241.

Harvard

Chen, E., Wang, J., Zhang, H., Zhang, Y., Jia, C., Min, X.,  and Liang, Y. (2021). Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer. Journal of Contemporary Brachytherapy, 13(3), pp.347-357. https://doi.org/10.5114/jcb.2021.106241

MLA

Chen, Enli et al. "Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer." Journal of Contemporary Brachytherapy, vol. 13, no. 3, 2021, pp. 347-357. doi:10.5114/jcb.2021.106241.

Vancouver

Chen E, Wang J, Zhang H, Zhang Y, Jia C, Min X et al. Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer. Journal of Contemporary Brachytherapy. 2021;13(3):347-357. doi:10.5114/jcb.2021.106241.

Introduction
To evaluate the efficacy and safety of iodine-125 (125I) seeds implantation for inoperable early-stage non-small cell lung cancer (NSCLC).

Material and methods
PubMed, Cochrane Library, Embase, China Biology Medicine disc (CBM), China National Knowledge Infrastructure (CNKI), and Wanfang Data were searched from inception until April 2020. Data were collected concerning overall survival, short-term efficacy, and complications. Meta-analysis was performed using R software (version 3.6.3).

Results
Nine studies involving 308 patients were included. Meta-analysis showed that the 1-, 2-, and 3-year survival rates were 0.98% (95% CI: 0.95-0.99%), 0.83% (95% CI: 0.77-0.89%), and 0.65% (95% CI: 0.55-0.75%), respectively; short-term local control rate (LCR) and effective rates were 0.99% (95% CI: 0.98-1.00%) and 0.92% (95% CI: 0.83-0.98%), respectively; 1-, 2-, and 3-year LCRs were 0.96% (95% CI: 0.83-1.00%), 0.94% (95% CI: 0.85-0.99%), and 0.95% (95% CI: 0.76-1.00%), respectively. Sub-group analysis of the prescribed dose found that when the prescribed dose was > 120 Gy, short-term efficacy and 1-year LCR were increased significantly (p < 0.01). The incidence of bleeding, pneumothorax, and radiation lung injury was 0.14% (95% CI: 0.07-0.21%), 0.19% (95% CI: 0.11-0.28%), and 0.00% (95% CI: 0.00-0.03%), respectively. Two studies involving 106 patients compared 125I seeds combined with chemotherapy versus chemotherapy alone for NSCLC. Results showed that compared with chemotherapy alone, 125I seeds combined with chemotherapy could improve short-term LCR (RR = 1.34, 95% CI: 1.09-1.65%, p = 0.005) and short-term effective rate (RR = 1.49, 95% CI: 1.14-1.96%, p = 0.004).

Conclusions
125I seeds implantation is safe and effective approach for the treatment of inoperable early-stage NSCLC, but high-quality clinical research is still needed to further confirm the findings.

keywords:

Analysis of the efficacy and safety of iodine-125 seeds implantation in the treatment of patients with inoperable early-stage non-small cell lung cancer

Enli Chen 1 , Juan Wang 2 , Hongtao Zhang 2 , Yuwei Zhang 1 , Chenfei Jia 1 , Xueya Min 1 , Yansong Liang 2

NSCLC, iodine-125, brachytherapy, meta-analysis

Enli Chen

¹

,

Juan Wang

²

,

Hongtao Zhang

²

,

Yuwei Zhang

¹

,

Chenfei Jia

¹

,

Xueya Min

¹

,

Yansong Liang

²